Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Sells $621,259.21 in Stock

Key Points

• Kiniksa Pharmaceuticals CFO Mark Ragosa sold 18,889 shares of stock for a total of $621,259.21, reducing his ownership by 41.15% to 27,009 shares worth approximately $888,326.01.
• Despite recent insider selling, Kiniksa traded at $32.72 with a market cap of $2.39 billion and positive quarterly earnings that beat analyst estimates by $0.05.
• Kiniksa Pharmaceuticals received multiple analyst upgrades, including a strong-buy rating from Wall Street Zen, and has a consensus rating of "Buy" with an average price target of $41.17.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 18,889 shares of the business's stock in a transaction on Monday, August 4th. The shares were sold at an average price of $32.89, for a total value of $621,259.21. Following the transaction, the chief financial officer owned 27,009 shares of the company's stock, valued at approximately $888,326.01. The trade was a 41.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Mark Ragosa also recently made the following trade(s):

• On Tuesday, June 3rd, Mark Ragosa sold 18,299 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $28.80, for a total value of $527,011.20.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ:KNSA traded down $0.35 during mid-day trading on Wednesday, hitting $32.72. 656,035 shares of the company's stock traded hands, compared to its average volume of 703,496. The company has a fifty day moving average of $28.63 and a 200 day moving average of $24.31. The company has a market capitalization of $2.39 billion, a P/E ratio of 818.20 and a beta of 0.14. Kiniksa Pharmaceuticals International, plc has a twelve month low of $17.82 and a twelve month high of $33.98.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. On average, research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KNSA has been the subject of several research reports. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Saturday. Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Jefferies Financial Group upped their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company upped their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of "Buy" and an average price target of $41.17.

Institutional Trading of Kiniksa Pharmaceuticals International

Several hedge funds and other institutional investors have recently bought and sold shares of KNSA. GAMMA Investing LLC grew its holdings in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares during the period. US Bancorp DE purchased a new position in Kiniksa Pharmaceuticals International during the first quarter worth approximately $33,000. Asset Management One Co. Ltd. purchased a new position in Kiniksa Pharmaceuticals International during the first quarter worth approximately $41,000. Wealthquest Corp purchased a new position in Kiniksa Pharmaceuticals International during the first quarter worth approximately $42,000. Finally, Lazard Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals International during the fourth quarter worth approximately $61,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.